Literature DB >> 3373234

Preventive effects of several chemicals against lethality of recombinant human tumor necrosis factor.

N Satomi1, A Sakurai, R Haranaka, K Haranaka.   

Abstract

Toxicity has been observed in mice receiving recombinant human tumor necrosis factor (rhTNF). In the present experiments, several chemicals were used to determine whether they could prevent the lethality of rhTNF without impairing its antitumor activity. Injection of phospholipase A2, cyclooxygenase, and lipoxygenase inhibitors at the same time as rhTNF administration could prevent the lethality of rhTNF, but the antitumor activity was also reduced. Urinastatin and reduced glutathione could prevent the lethality while reducing the activity. In contrast, by pretreatment with O2 scavengers, the lethality of rhTNF was markedly reduced without impairment of the antitumor activity of rhTNF. Antihistamines exerted no influence on the lethality of rhTNF. Histopathologic examinations have demonstrated that the capillaries of the tumor tissue show aggregation of platelets and formation of fibrin adherent to the vascular surface after TNF administration. Heparin or protamine revealed no effects against the lethality of rhTNF. These results strongly suggest that the arachidonic cascade is deeply related to the antitumor activity of TNF and its side effects. Pretreatment with O2 scavengers, especially bismuth subnitrate, could prevent the lethality of rhTNF without impairing its antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3373234

Source DB:  PubMed          Journal:  J Biol Response Mod        ISSN: 0732-6580


  7 in total

1.  Relationships between tumour necrosis factor, eicosanoids and platelet-activating factor as mediators of endotoxin-induced shock in mice.

Authors:  A K Myers; J W Robey; R M Price
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

2.  Acute effects of human recombinant tumor necrosis factor-alpha on the cerebral vasculature of the rat in both normal brain and in an experimental glioma model.

Authors:  G Kido; J L Wright; R E Merchant
Journal:  J Neurooncol       Date:  1991-04       Impact factor: 4.130

3.  Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor alpha in normal and tumor-bearing mice.

Authors:  J A Krosnick; J K McIntosh; J J Mulé; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Tumor necrosis factor alpha and the anemia associated with murine malaria.

Authors:  K L Miller; P H Silverman; B Kullgren; L J Mahlmann
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

5.  Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury.

Authors:  A Seekamp; J S Warren; D G Remick; G O Till; P A Ward
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

6.  Glucocorticoids as cytokine inhibitors: role in neuroendocrine control and therapy of inflammatory diseases.

Authors:  G Fantuzzi; P Ghezzi
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

7.  HeLa cell transformants overproducing mouse metallothionein show in vivo resistance to cis-platinum in nude mice.

Authors:  H Toyoda; T Mizushima; M Satoh; N Iizuka; A Nomoto; H Chiba; M Mita; A Naganuma; S Himeno; N Imura
Journal:  Jpn J Cancer Res       Date:  2000-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.